Home
    • Plans Blog Contact
    Tenax Therapeutics Inc logo

    Tenax Therapeutics Inc

    TENX
    Last price US$1.80
    Market cap US$16.8m
    12M price change -69.75%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Apple IncAAPL Research alternative
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Tenax Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmona Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Tenax Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jul 31, 2026

    Quarterly result summary

    Net loss was -$17.8M (from $10.9M). Cash was $118M.

    Net loss -$17.8M from $10.9M
    Cash $118M reported

    What changed

    • Net loss was -$17.8M (from $10.9M).

    Guidance / outlook

    we expect to have topline data from the LEVEL clinical trial in August,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Jul 31, 2026 SEC filing 8-K Jul 31, 2026 SEC filing 10-Q May 12, 2026 Earnings release Earnings release May 12, 2026 SEC filing 8-K May 12, 2026 SEC filing 10-K Mar 10, 2026 Earnings release PRESS RELEASE Mar 10, 2026 SEC filing FORM 8-K Mar 10, 2026 SEC filing FORM 8-K Nov 12, 2025 SEC filing 10-Q Nov 12, 2025 Earnings release PRESS RELEASE Nov 12, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    Tenax Therapeutics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.84/5
    Tenax Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
    Tenax Therap... TENX US$16.8m

    Net Margin

    Score 2.10/5
    Tenax Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
    Tenax Therap... TENX US$16.8m

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.00/5
    Tenax Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as , also exhibit high scores.
    Tenax Therap... TENX US$16.8m

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Tenax Therapeutics Inc logo

    Tenax Therapeutics Inc

    US$1.80

    US$16.8m

    -86.61%

    -69.75%